Should I buy Lantheus stock in 2025?
Is Lantheus stock a buy right now?
ScoreLantheus Holdings (NASDAQ: LNTH) stands at an intriguing position in the healthcare sector as of late May 2025, with its shares trading around $73.86 and an average daily trading volume near 1.07 million. As a leading player in the expanding radiopharmaceutical market, Lantheus combines innovation with a strategic focus on imaging agents and diagnostics—most notably its flagship PYLARIFY and DEFINITY products. While the recent Q1 results indicated a slight revenue uptick (+0.8% YoY), net income was lower compared to the previous year, largely influenced by temporary headwinds such as product mix shifts and strategic investments. Nevertheless, management continues to bolster the company’s pipeline; the completed acquisition of Evergreen Theragnostics and the pending addition of Life Molecular Imaging are likely to diversify revenue and enhance long-term resilience. Market sentiment, while cautious due to the technical downtrend and modestly reduced full-year guidance, sees upside on the back of robust cash reserves, continuous innovation, and emerging opportunities, especially in Alzheimer’s diagnostics. In a healthcare sector seeking high-impact innovation, over 34 national and international banks have set a collective target price of $96 for LNTH, reflecting strong institutional confidence. With its decisive focus and growing market opportunities, Lantheus presents itself as a stock worth close investor attention at its current levels.
- ✅Leadership in radiopharmaceuticals with dominant products in oncology and cardiology imaging.
- ✅Robust pipeline, including MK-6240 for Alzheimer’s, addresses significant unmet medical needs.
- ✅Strategic acquisitions expected to broaden revenue streams and operational scale.
- ✅Strong gross profit margins and healthy free cash flow support continued R&D investment.
- ✅Exposure to growing diagnostic imaging markets with global expansion potential.
- ❌Stock currently trades below all major moving averages, signaling technical weakness.
- ❌Recent earnings volatility due to acquisition integration and competitive pressures.
Score- ✅Leadership in radiopharmaceuticals with dominant products in oncology and cardiology imaging.
- ✅Robust pipeline, including MK-6240 for Alzheimer’s, addresses significant unmet medical needs.
- ✅Strategic acquisitions expected to broaden revenue streams and operational scale.
- ✅Strong gross profit margins and healthy free cash flow support continued R&D investment.
- ✅Exposure to growing diagnostic imaging markets with global expansion potential.
Is Lantheus stock a buy right now?
- ✅Leadership in radiopharmaceuticals with dominant products in oncology and cardiology imaging.
- ✅Robust pipeline, including MK-6240 for Alzheimer’s, addresses significant unmet medical needs.
- ✅Strategic acquisitions expected to broaden revenue streams and operational scale.
- ✅Strong gross profit margins and healthy free cash flow support continued R&D investment.
- ✅Exposure to growing diagnostic imaging markets with global expansion potential.
- ❌Stock currently trades below all major moving averages, signaling technical weakness.
- ❌Recent earnings volatility due to acquisition integration and competitive pressures.
Score- ✅Leadership in radiopharmaceuticals with dominant products in oncology and cardiology imaging.
- ✅Robust pipeline, including MK-6240 for Alzheimer’s, addresses significant unmet medical needs.
- ✅Strategic acquisitions expected to broaden revenue streams and operational scale.
- ✅Strong gross profit margins and healthy free cash flow support continued R&D investment.
- ✅Exposure to growing diagnostic imaging markets with global expansion potential.
- What is Lantheus?
- How much is Lantheus stock?
- Our full analysis on Lantheus stock
- How to buy Lantheus stock in PH?
- Our 7 tips for buying Lantheus stock
- The latest news about Lantheus
- FAQ
What is Lantheus?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | U.S.-based company operating in the global healthcare and radiopharmaceutical industry. |
| 💼 Market | NASDAQ (USD) | Listed on NASDAQ; shares can be easily traded by international investors. |
| 🏛️ ISIN code | US5165441032 | Unique securities identifier for Lantheus Holdings on global exchanges. |
| 👤 CEO | Brian Markison | Leads recent acquisitions and transition toward innovative radiopharmaceuticals. |
| 🏢 Market cap | $5.11 billion | Reflects mid-cap size with growth potential and active M&A strategy. |
| 📈 Revenue | $1.55–$1.59 billion (FY25E) | Guided to modest year-over-year growth; pipeline products may further boost future sales. |
| 💹 EBITDA | ~$450 million (projected FY25) | Strong cash generation; supports additional R&D and acquisition activities. |
| 📊 P/E Ratio (Price/Earnings) | 21.04 (TTM) / 10.76 (forward) | Lower forward P/E suggests market expects slower near-term earnings growth. |
How much is Lantheus stock?
The price of Lantheus stock is falling this week. As of now, Lantheus Holdings (LNTH) is trading at $73.86, with a 24-hour decrease of $0.89 or -1.19%, and a notable weekly drop of 9.08%.
| Market capitalization | $5.11 billion |
|---|---|
| Average daily volume (3 months) | 1,071,788 shares |
| Price-to-earnings (P/E) ratio | 21.04 |
| Dividend yield | 0% |
| Beta | 0.23 |
With a very low beta of 0.23, the stock shows limited volatility compared to the broader market—something investors in the PH may consider when diversifying global portfolios.
Compare the best brokers in the Philippines!Compare brokersOur full analysis on Lantheus stock
Following an exhaustive review of Lantheus Holdings’ most recent financial disclosures and a granular assessment of its share price action over the past three years, our proprietary analysis—incorporating a blend of financial ratios, technical patterns, peer benchmarking, and real-time market signals—has generated a distinctly optimistic perspective on the stock. Given Lantheus’s dynamic restructuring, robust pipeline, and current technical setup, one must ask: could Lantheus stock now represent a compelling re-entry point for investors seeking to capitalize on the next wave of innovation in healthcare diagnostics in 2025?
Recent Performance and Market Context
Despite its recent corrective trend, Lantheus continues to exhibit resilience against a challenging global healthcare backdrop. As of May 27, 2025, LNTH trades at $73.86, close to its 52-week low of $73.11, marking a 6.51% decline year-over-year and an 18.40% decrease over six months. While this retreat reflects short-term headwinds common in the radiopharmaceutical sector, it also positions the stock at an intriguing valuation for new capital.
- Strategic Acquisitions: The acquisition of Evergreen Theragnostics (April 2025) and the planned integration of Life Molecular Imaging (expected Q2 2025) strategically expand Lantheus’s innovative radiopharma platform and geographical reach.
- Focused Portfolio: The divestiture of the legacy SPECT business to SHINE Technologies illustrates management’s deliberate pivot towards higher-growth, next-generation PET diagnostics and therapeutics.
- Pipeline Advancements: Lantheus’s radiodiagnostic for Alzheimer’s (MK-6240) achieved primary endpoints and is on track for an NDA filing in Q3 2025—opening potential access to a $1.5 billion untapped market.
- Sector Tailwinds: The global radiopharmaceutical market is forecast to accelerate rapidly due to aging demographics and the increasing prevalence of complex cancers, favoring market leaders like Lantheus.
For investors in the Philippine market seeking diversification via U.S. healthcare innovators, Lantheus emerges as a potent candidate—not only as a defensive asset but also as a vehicle for growth.
Technical Analysis
Current technicals for LNTH highlight a potentially attractive contrarian setup:
- Oversold Indicators: With the 14-day RSI at 26.09 and Stochastic %K at 2.34, LNTH is registering extremely oversold conditions. Historically, such readings have often preceded powerful rebound rallies, especially for stocks with solid fundamentals.
- MACD and Moving Averages: While MACD stands at -6.52 and the stock remains below all key moving averages (20, 50, 100, and 200-day), this “technical washout” scenario is a classic precursor to mean-reversion opportunities. Notably, LNTH has approached its 52-week low at $73.11, forming a strong support base.
- Death Cross Event: The recent “death cross” (50-day MA crossing below 200-day MA) on May 19, often seen as a lagging indicator, can paradoxically mark capitulation selling—an environment where forward-looking investors accumulate positions.
- Next Resistance Levels: The rebound targets are $87.91 (20-day MA) and $94.78 (50-day MA), representing 19% and 28% upside potentials, respectively, from current prices.
For active traders and medium-term investors, these combined signals suggest LNTH could be embarking on a new bullish phase, especially if positive catalysts or earnings surprises materialize.
Fundamental Analysis
Examining Lantheus’s fundamentals reveals a business in the midst of a strategic evolution, underpinned by robust financials and attractive forward metrics:
- Revenue and Profitability: Q1 2025 revenue was $372.8 million (up 0.8% YoY), and FY 2025 guidance projects $1.550–$1.585 billion. Profit margins remain healthy at 67%, with free cash flow at $98.8 million, underscoring ongoing business strength.
- Earnings Power: Even after revising guidance, the forward adjusted EPS estimate of $6.60–$6.70 positions LNTH at a very reasonable forward P/E of 10.76—well below healthcare tech sector averages, suggesting undervaluation.
- Product and Market Leadership: PYLARIFY maintains its lead in prostate cancer imaging, while DEFINITY’s ongoing growth in cardiac imaging fortifies the company’s recurring revenue base.
- Innovation and Pipeline: Lantheus is now focused almost exclusively on radiopharmaceutical innovation—particularly in oncology and neurology—where barriers to entry are high, regulatory moats are defensible, and long-run growth is structurally supported.
- Balance Sheet Strength: Boasting $938.5 million in cash, Lantheus is well-equipped to fund future R&D, navigate integration of new acquisitions, and weather macroeconomic fluctuations.
Valuation multiples (P/S at 3.46, P/B at 4.39) are consistent with high-quality, innovation-driven pharma companies, and the company’s capital allocation strategy is outwardly growth-focused.
Volume and Liquidity
LNTH shares are actively traded, with an average daily volume of 1.07 million shares—assuring ample liquidity for institutional and retail participants from the Philippines and beyond. High average volume, particularly during periods of price pressure, indicates robust market confidence and supports efficient price discovery.
The current float and spread also leave space for dynamic price movements, making technical and event-driven positioning especially relevant in the coming quarters.
Catalysts and Positive Outlook
Multiple tangible catalysts are lined up in the months ahead:
- Product Approvals: The NDA filing and potential FDA approval for MK-6240 (Alzheimer’s diagnostic) in Q3 2025 could open up a high-growth vertical.
- Strategic Acquisitions: The integration of Evergreen Theragnostics and Life Molecular Imaging is expected to both boost revenue diversification and provide leverage to emerging diagnostic and therapeutic modalities.
- Portfolio Realignment: By exiting commoditized legacy businesses (e.g., SPECT), Lantheus is sharpening its growth profile and reducing operational drag.
- Emerging Markets: The company’s focus on global partnerships and contract wins with hospitals and imaging centers ensures a solid base of recurring revenues.
- Favorable Regulatory Environment: Increased focus on early cancer and Alzheimer’s detection, coupled with likely supportive reimbursement for PET imaging, presents a tailwind for adoption and market share gains.
Given these elements, the risk-reward balance appears particularly appealing for equity portfolios with a technology and healthcare orientation.
Investment Strategies
Lantheus offers differentiated entry points for varying investor profiles:
- Short-Term:
- Rebound potential from heavily oversold technical readings, especially if momentum shifts on upcoming earnings (late July–early August).
- Ideal timing for active traders could be positioning at current support near $73, with clear stop-loss discipline below recent lows.
- Medium-Term:
- Accumulation on dips ahead of the Q3 2025 MK-6240 NDA catalyst and completion of the Life Molecular Imaging acquisition, which could reset sentiment and valuation multiples.
- Anticipating stabilization as integration milestones are achieved, followed by upward re-rating.
- Long-Term:
- Lantheus’s business transformation, pipeline depth, and secular radiopharma tailwinds contribute to a compelling long-term growth thesis.
- Opportunity to benefit from compounding innovation monetization across oncology, neurology, and cardiovascular diagnostics.
- Despite the absence of a dividend, capital appreciation prospects seem robust, with substantial optionality on successful commercialization of late-stage assets.
A layered approach—combining an initial position at technical lows and adding on confirmation of accelerating momentum or further positive news—could prove especially effective.
Is It the Right Time to Buy Lantheus?
Synthesizing the full spectrum of technical, fundamental, and strategic inputs, Lantheus stands today at a turning point where downside risk appears increasingly priced in, and the path to upside surprises grows stronger. The stock’s convergence of oversold technicals, attractive forward valuation, major near-term catalysts, and focus on high-value, innovative diagnostics lays the groundwork for renewed investor interest.
For Philippine investors seeking access to global healthcare breakthroughs—and specifically, to the rapidly expanding radiopharmaceutical sector—Lantheus seemingly represents an excellent opportunity at a moment when most of Wall Street appears overly cautious. The fundamentals, pipeline momentum, and structural sector demand together justify fresh optimism and reinforce LNTH’s potential reemergence as a sector leader in 2025.
Lantheus is entering a new chapter defined by disciplined capital allocation, innovation leadership, and operational focus, and the current share price may set the stage for significant upside in the coming months and years for those with a forward-looking approach and an appetite for dynamic healthcare opportunities.
How to buy Lantheus stock in PH?
Buying Lantheus (LNTH) stock online is simpler and more secure than ever for investors in the Philippines, thanks to regulated international brokers. You have two main ways to access LNTH: a cash (spot) purchase, where you own the shares outright, or trading via Contracts for Difference (CFDs), which track the price movements of the stock using leverage. Both options can be managed entirely online, providing flexibility and transparency. To make the best choice, it's important to compare brokers on fees and features—a handy broker comparison is featured further down this page.
Cash Buying
A cash purchase means you buy actual Lantheus shares on the NASDAQ and become a shareholder, with all the corresponding rights (excluding dividends, since Lantheus currently does not pay any). Philippine investors typically pay a fixed commission per order, usually ranging from PHP 150 to PHP 400, depending on the broker, plus a small foreign exchange fee when transferring pesos to USD.
Important example
Example: If the LNTH share price is $73.86 (about PHP 4,150 at ₱56/USD), with $1,000 (around PHP 56,000), you could buy approximately 13 shares after factoring in a $5 commission.
✔️ Gain scenario:
If the share price rises by 10% to $81.25, your investment would now be worth $1,100.
Result: +$100 gross gain, or +10% on your investment.
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Lantheus’s share price without owning the actual stock. The main fees here are the ‘spread’ (the small markup between buy/sell prices) and, if you hold positions overnight, a daily financing charge (often around 0.015%–0.05% per day of total exposure).
Important example
Example: With $1,000, you open a CFD position on LNTH with 5x leverage. This gives you the same market exposure as having invested $5,000.
✔️ Gain scenario:
If the share price rises by 8%, your leveraged position increases by 8% × 5 = 40%.
Result: +$400 gain on your $1,000 initial outlay (excluding fees).
Final Advice
Before investing, always compare brokers’ fees, currency conversion costs, platform safety, and available features to find the best match for your needs—our comparison section below can help. Whether you choose direct share ownership for long-term growth or CFDs for active and leveraged trading depends on your investment objectives, risk tolerance, and strategy. Take the time to assess your goals, then proceed confidently with your chosen method.
Compare the best brokers in the Philippines!Compare brokersOur 7 tips for buying Lantheus stock
| 📊 Step | 📝 Specific tip for Lantheus |
|---|---|
| Analyze the market | Assess the healthcare sector and radiopharmaceutical industry, noting that Lantheus leads in diagnostic imaging and is actively expanding through acquisitions and a strong innovation pipeline. |
| Choose the right trading platform | For investors in the Philippines, select a trusted broker that offers access to US stocks like Lantheus on the NASDAQ and provides competitive currency conversion rates for PHP to USD. |
| Define your investment budget | Plan the amount you’re willing to invest based on your financial goals, keeping in mind that Lantheus does not pay dividends and has experienced recent price volatility. |
| Choose a strategy (short or long term) | Consider a long-term strategy to benefit from Lantheus’s growth potential in radiopharmaceuticals, Alzheimer’s diagnostics, and pipeline expansion, while being aware of near-term volatility. |
| Monitor news and financial results | Stay updated on Lantheus’s quarterly reports, major acquisitions, and product pipeline developments like MK-6240, as these have a strong impact on share price movements. |
| Use risk management tools | Utilize stop-loss orders and diversify your portfolio to protect your investment, especially given Lantheus’s current technical downtrend and market uncertainties. |
| Sell at the right time | Regularly review technical indicators and major company news; consider taking profits if the price rebounds sharply or if market sentiment turns negative after earnings or product updates. |
The latest news about Lantheus
Lantheus has successfully advanced its Alzheimer’s radiodiagnostic MK-6240, achieving primary endpoints in pivotal studies. In the past week, the company confirmed that MK-6240 met all primary endpoints in two major clinical trials, marking a significant milestone in its neuroimaging pipeline. An NDA (New Drug Application) filing is planned for Q3 2025, potentially opening new revenue streams and strengthening Lantheus’s position in the diagnostic imaging market, especially as demand for advanced Alzheimer’s diagnostics rises globally, including in the increasingly health-conscious ASEAN region. This progress is particularly impactful for health systems in the Philippines seeking to adopt innovative diagnostic technologies for neurological disorders.
The acquisition of Evergreen Theragnostics and pending acquisition of Life Molecular Imaging are expected to diversify the company’s radiopharmaceutical portfolio. Lantheus finalized the $250 million Evergreen Theragnostics deal on April 1, 2025, and is on track to complete the $350 million purchase of Life Molecular Imaging by the end of Q2 2025. These acquisitions reinforce its strategy to focus on innovative PET diagnostics and therapeutics, which broadens its potential offering base. For analysts in the Philippines, this expansion signals opportunities to introduce new global imaging solutions in the local healthcare market and may encourage partnerships with regional distributors and medical centers.
Strategic divestiture of the SPECT business at the start of May aligns Lantheus with global shifts toward advanced PET imaging. The announced sale of its legacy SPECT division to SHINE Technologies enables Lantheus to redeploy resources into higher-growth PET and radiotherapeutic technologies. This focus is in line with current healthcare trends in Southeast Asia, where demand is shifting toward high-precision, next-generation imaging for oncology and neurology—fields where Lantheus aims to lead. The move is likely to enhance operational efficiency and the relevance of Lantheus products in technologically advancing Philippine hospitals.
Lantheus continues to demonstrate market leadership in prostate cancer imaging with PYLARIFY, sustaining strong revenue contributions despite competitive pressures. PYLARIFY sales reached $257.7 million in Q1 2025, remaining robust despite marginal year-over-year contraction and growing competition. The agent’s adoption for PSMA PET scans supports advanced cancer care initiatives in tertiary centers across Asia-Pacific, and its performance underscores the global demand for cutting-edge oncology diagnostics—a trend mirrored by private and public sector investments in the Philippine healthcare industry.
Despite a recent technical downtrend, Lantheus maintains strong financial flexibility and is well-positioned for long-term sector growth. While the stock has declined to a 52-week low and current sentiment is bearish, Lantheus retains a liquid balance sheet with $938.5 million in cash. This financial strength supports ongoing R&D, acquisitions, and market expansion—crucial for sustaining innovation and partnerships, including possible collaborations with Filipino healthcare institutions. With the radiopharmaceutical market predicted to expand, Lantheus’s strategic focus and resource base provide a constructive foundation for medium-term recovery and growth.
FAQ
What is the latest dividend for Lantheus stock?
Lantheus stock does not currently pay any dividends. The company has never declared or distributed a dividend to shareholders, reflecting its strategy to reinvest earnings into the business. Lantheus focuses on growth through acquisitions and research in radiopharmaceuticals, and as such, investors should not expect a regular income from dividends for the foreseeable future.
What is the forecast for Lantheus stock in 2025, 2026, and 2027?
Based on its current share price of $73.86, optimistic projections place Lantheus at $96.02 by the end of 2025, $110.79 by end of 2026, and $147.72 at the end of 2027. Lantheus is positioned in a growing radiopharmaceutical market, and recent acquisitions alongside pipeline developments could enhance its long-term growth prospects amid rising demand for innovative diagnostics.
Should I sell my Lantheus shares?
Given Lantheus’s strong position in the radiopharmaceutical sector, ongoing strategic acquisitions, and robust cash reserves, holding shares may be a sound choice for investors with a medium- to long-term outlook. The stock is currently undervalued compared to its future potential, especially as it pivots to high-growth markets like Alzheimer’s diagnostics. Continued product innovation and focus on core business lines support a positive long-term scenario, despite short-term volatility.
Are dividends or capital gains from Lantheus stock subject to Philippine taxes?
Yes, Philippine tax residents are generally subject to tax on capital gains realized from selling Lantheus shares and on any dividends if declared. For foreign shares like Lantheus, capital gains are subject to regular income tax rates, and if dividends are paid in the future, they may be subject to a US withholding tax of 30% (which may be reduced to 25% for PH residents), with no local tax credits available. Lantheus shares are not eligible for Philippine tax-advantaged accounts like PERA.
What is the latest dividend for Lantheus stock?
Lantheus stock does not currently pay any dividends. The company has never declared or distributed a dividend to shareholders, reflecting its strategy to reinvest earnings into the business. Lantheus focuses on growth through acquisitions and research in radiopharmaceuticals, and as such, investors should not expect a regular income from dividends for the foreseeable future.
What is the forecast for Lantheus stock in 2025, 2026, and 2027?
Based on its current share price of $73.86, optimistic projections place Lantheus at $96.02 by the end of 2025, $110.79 by end of 2026, and $147.72 at the end of 2027. Lantheus is positioned in a growing radiopharmaceutical market, and recent acquisitions alongside pipeline developments could enhance its long-term growth prospects amid rising demand for innovative diagnostics.
Should I sell my Lantheus shares?
Given Lantheus’s strong position in the radiopharmaceutical sector, ongoing strategic acquisitions, and robust cash reserves, holding shares may be a sound choice for investors with a medium- to long-term outlook. The stock is currently undervalued compared to its future potential, especially as it pivots to high-growth markets like Alzheimer’s diagnostics. Continued product innovation and focus on core business lines support a positive long-term scenario, despite short-term volatility.
Are dividends or capital gains from Lantheus stock subject to Philippine taxes?
Yes, Philippine tax residents are generally subject to tax on capital gains realized from selling Lantheus shares and on any dividends if declared. For foreign shares like Lantheus, capital gains are subject to regular income tax rates, and if dividends are paid in the future, they may be subject to a US withholding tax of 30% (which may be reduced to 25% for PH residents), with no local tax credits available. Lantheus shares are not eligible for Philippine tax-advantaged accounts like PERA.
